CREATININE
Detail Description
Clinical Use
Detect chronic kidney disease (CKD) in adults
Monitor CKD therapy and/or progression in adults
Clinical Background
About 37 million people in the United States are currently affected by CKD, and the prevalence of ensuing kidney failure is rising.1 Since evidence has shown that treatment at earlier stages is generally effective in preventing or delaying adverse outcomes, monitoring patients with and at risk for CKD becomes critically important for decreasing morbidity and mortality.
The Kidney Disease Improving Global Outcomes (KDIGO) guideline defines CKD by the presence of glomerular filtration rate (GFR) <60 mL/min/1.73m2 for >3 months and/or evidence of kidney damage (eg, structural abnormalities, histologic abnormalities, albuminuria, urinary sediment abnormalities, renal tubular disorders, and/or history of kidney transplantation) for >3 months.2 Thus, monitoring should include tests for GFR, albuminuria, and urine sediment.
GFR has traditionally been estimated based on 24-hour creatinine clearance; however, a calculation of estimated glomerular filtration rate (eGFR) is now recommended by the National Institutes of Health (NIH) and the National Kidney Foundation. eGFR based on serum creatinine and/or cystatin C is a simpler and generally more reliable test.
Includes
eGFR
Methodology
Spectrophotometry (SP)
Reference Range(s)
Creatinine
Age Male (mg/dL) Female (mg/dL)
≤2 days 0.79-1.58 0.79-1.58
3-27 days 0.35-1.23 0.35-1.23
1 month-9 years 0.20-0.73 0.20-0.73
10-12 years 0.30-0.78 0.30-0.78
13-15 years 0.40-1.05 0.40-1.00
16-17 years 0.60-1.20 0.50-1.00
18-19 years 0.60-1.26 0.50-1.00
20-49 years 0.60-1.35 0.50-1.10
50-59 years 0.70-1.33 0.50-1.05
60-69 years 0.70-1.25 0.50-0.99
70-79 years 0.70-1.18 0.60-0.93
≥80 years 0.70-1.11 0.60-0.88For patients >49 years of age, the upper reference limit for creatinine is approximately 13% higher for people identified as African-American.
eGFR Non-African American ≥60 mL/min/1.73m2
eGFR African American ≥60 mL/min/1.73m2